Authorities Recognize a Need to Encourage Pediatric Drug Development

Addressing the unnacceptable lack of pediatric labeling requires not only economic incentives but also an understanding of the unique difficulties involved in pediatric studies.

Related Content:

Feature ArticleApplied Clinical Trials-01-01-2002

A Closer Look at the 1572: Interpreting the FDA's Statement of Investigator Form

Japanese R&D: Branching Out

A Closing Thought: Prescribing Fixes for a Broken System